Clinical Scorecard: Evaluation of the Safety and Effectiveness of Cytokine-Induced Killer Cell Therapy in Gastric Cancer: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Cytokine-induced killer (CIK) cell therapy is associated with enhanced anti-tumor immunity based on available studies.
Target Population
Care Setting
Key Highlights
CIK/DC-CIK therapy combined with chemotherapy shows pooled hazard ratios indicating OS HR 0.60, PFS HR 0.60, and DFS HR 0.70.
Guideline-Based Recommendations
Diagnosis
Management
Consider CIK or DC-CIK immunotherapy in combination with chemotherapy based on available evidence.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with gastric cancer, primarily studied in Chinese clinical trials.
CIK therapy is a viable adjunct to chemotherapy with a favorable safety profile.
Clinical Best Practices
Further studies are needed to validate findings in diverse populations.
